watch cbsn live by kate gibson updated on september 23 2019 5 24 pm moneywatch torrent pharmaceuticals is expanding a recall of blood pressure medication possibly tainted with a cancer causing chemical the expansion is the fifth by torrent involving widely used losartan potassium tablets sold nationwide at retailers including walmart regulators first moved to pull heart drugs with potentially deadly contaminants from store shelves last year the contaminant behind the latest torrent recall is also the same one that prompted novartis to halt distribution of generic versions of the popular heartburn drug zantac earlier in the week torrent on thursday said it was recallingan additional five lots of medication used to treat hypertension after the discovery in the tablets of a chemical called nmba for n nitroso n methyl 4 aminobutyric acid the u s food and drug administration for the past 14 months has overseen a slew of recalls for a type of generic blood pressure medication produced in china and india and tainted with nmba ndma n nitrosodimethylamine or ndea n nitrosodiethylamine the fda has said the impurities in the generic blood pressure pills known as arb drugs for angiotensin ii receptor blocker drugs may be the result of chemical reactions that occur in the manufacturing process or from the reuse of materials such as solvents if 8 000 people took the highest dose from recalled batches every day for four years there would likely be one additional case of cancer over the life of those people the agency estimates torrent said it s only recalling lots containing nmba above what the fda considers acceptable for daily use overall torrent has recalled more than 300 lots of blood pressure pills since the summer of 2018 it s among a dozen drugmakers that have recalled blood pressure drugs made with active ingredients from suppliers in china and india other companies to announce recalls include mylan aurobindo pharma camber pharmaceuticals macleods pharmaceuticals legacy pharmaceuticals gsms inc wp westminster pharmaceuticals major pharmaceuticals prinston pharmaceuticals sandoz novartis and teva pharmaceuticals while regulators were mostly concerned about the class of hypertension drugs known as arbs the fda and europe s top drug regulator last week said they were reviewing ndma levels in zantac and its generic forms within days novartis sandoz unit said it was stopping worldwide distribution of generic versions of zantac the maker of zantac sanofi said it had no plans to halt distribution or sales of the medication in the u s or europe citing fda reports that mere trace amounts of ndma were identified we are conducting our own robust investigations to ensure we continue to meet the highest quality safety and quality standards sanofi said in a statement one consumer advocate however called on the fda to step up its efforts saying distribution stoppages and even recalls are insufficient responses to what the advocated called an ongoing public health threat the fda should consider requiring any generic manufacturer that has had these issues to stop production until the issues have been resolved according to adam garber consumer watchdog at u s pirg short of curtailing production the fda should be inspecting every version of this medication since it seems to be a systemic problem and it s multiple manufacturers that we re talking about garber told cbs moneywatch at this point we should be looking at alternative versions and stopping the sale of the versions that do have these impurities said garber who stressed he was not advocating people taking heart medication to stop given the potential adverse health risks that move would entail an fda spokesperson said the agency has identified numerous alternative versions and offers an official listof affected products and products without impurities for the public to review based on our current assessments including lab testing the agency has identified 43 arb medications that have been determined not to contain any nitrosamine impurities the spokesperson emailed as we continue our assessments and as companies continue to manufacture arbs without nitrosamine impurities to replenish the u s supply we expect this figure to rise because arbs treat serious medical conditions the fda urges patients to continue taking their current medicine until a doctor or pharmacist gives a replacement or a different treatment option the spokesperson added first published on september 20 2019 5 06 pm 2019 cbs interactive inc all rights reserved be in the know get the latest breaking news delivered straight to your inbox copyright 2020 cbs interactive inc all rights reserved quotes delayed at least 15 minutes market data provided by ice data services ice limitations powered and implemented by factset news provided by the associated press legal statement 